BioAdvance is a venture capital investment firm based in Conshohocken, Pennsylvania, that specializes in funding early-stage life sciences companies in Southeastern Pennsylvania. Established in 2002 with $33 million from the Commonwealth of Pennsylvania's tobacco settlement funds, BioAdvance manages the Greenhouse Fund, which has a total of $50 million available for investment. The firm focuses on therapeutics, medical devices, diagnostics, and platform technologies aimed at improving human health. Since its inception, BioAdvance has committed over $40 million to more than 50 seed-stage companies and 17 pre-seed companies, supporting the development of products to address various health issues, including Alzheimer's disease, cancer, obesity, and respiratory illnesses. By fostering innovation in the healthcare sector, BioAdvance has positioned itself as a leading investor in the region.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Phrase Health, Inc. is a Philadelphia-based company founded in 2018 that specializes in software solutions for the healthcare sector. The company focuses on helping hospitals monitor and analyze the information available to doctors and nurses at the point of care, thereby enhancing the quality of care delivered to patients. Through its innovative technology, Phrase Health aims to streamline communication and improve clinical decision-making in healthcare settings.
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.
Phrase Health, Inc. is a Philadelphia-based company founded in 2018 that specializes in software solutions for the healthcare sector. The company focuses on helping hospitals monitor and analyze the information available to doctors and nurses at the point of care, thereby enhancing the quality of care delivered to patients. Through its innovative technology, Phrase Health aims to streamline communication and improve clinical decision-making in healthcare settings.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
Opsidio
Venture Round in 2017
A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .
Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.
Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.
CytoVas LLC develops informatics platform that provides information on novel cellular markers of disease progression and individual treatment response to clinicians and drug developers. The company's platforms include CLOUD CYTOMICS and CytoVas Vascular Health Profile. CLOUD CYTOMICS provides automated data collection, mining, and modeling solutions to clinical researchers. CytoVas Vascular Health Profile provides cytometric vascular health event detection test for clinical studies. The company was incorporated in 2010 and is headquartered in Philadelphia, Pennsylvania.
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.
Group K Diagnostics, Inc. develops and manufactures a point-of-care diagnostic device for testing liver function. The company offers MultiDiagnostic, a multi-test modular point of care (POC) diagnostic test using paper-based microfluidics which provides three diagnostics with one blood drop. The company also develops a mobile and desktop software that allows patients to upload the picture of the sample card on the application and read the results. Group K Diagnostics, Inc. was founded in 2016 and is based in Philadelphia, Pennsylvania.
TalexMedical, LLC develops and manufactures a medical device for the treatment of external ear deformities in newborns. The company’s product includes Infantear which is a class I medical device and a nonsurgical ear molding system that is applied in the outpatient setting for replacing surgical ear procedure. Further, the company’s product is customizable, made of soft materials and treats the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life. The company caters primarily to the pediatricians. TalexMedical, LLC was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.
Keriton LLC specializes in a pumped breast milk management system tailored for neonatal intensive care units (NICUs). Founded in 2016 and based in Philadelphia, Pennsylvania, the company addresses the challenges of breast milk management, which is often manual and error-prone. Its platform allows for real-time tracking of milk inventory, feeding orders, and provides notifications for expiry dates and misfeeds. Additionally, it enables nurses to share media with mothers and offers insights into lactating mothers' milk production patterns. By automating and validating the breast milk management process, Keriton significantly reduces the time nurses spend on these tasks, lowers the risk of errors, and creates an audit trail for compliance. The system aims to enhance the pumping experience for mothers, which is linked to better clinical outcomes for infants. Keriton's approach aligns with the goals of improving patient outcomes, reducing costs, and fostering better family engagement, presenting a potential return on investment for hospitals.
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.
Penn State Health Milton S. Hershey Medical Center is a 551-bed Level I regional trauma center. As Central Pennsylvania’s only academic medical center and home to the Children’s Hospital at Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine, we are looked to as a resource for the most complex adult and pediatric cases. We have earned ANCC Magnet Recognition, which confirms our commitment to provide a professional environment that supports staff development and quality patient care.
Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company has developed Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. It engages patients in managing these risks through targeted programs and interventions. The platform captures essential patient data at the point of care, facilitating value-based reimbursement and streamlining the alignment of provider and payer interests. By focusing on real-time patient engagement and data collection, Noble.MD aims to enhance risk identification, coding, and management in modern healthcare settings.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.
Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.
Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.
RiboNova is a biomedical research company in the Lankenau Institute for Medical Research.
The company develops a small molecule drugs against a new family of targets, defective transfer RNAs. Its focus is on novel therapies for the treatment of serious rare diseases, including mitochondrial disease and certain cancers.
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria.
Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections.
Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.
Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.
CarePartners Plus LLC is a healthcare data and information company based in Horsham, Pennsylvania, established in 2009. The company specializes in patient management solutions, offering Wellby, a cloud-based patient engagement system designed to enhance health outcomes by facilitating better patient-provider interactions. CarePartners Plus provides a range of services including patient engagement, caregiver management, care coordination, and cost containment, aimed at hospitals, physician groups, and various stakeholders in the healthcare system. Its technology captures and analyzes patient-generated data in real time, aligning with business models that prioritize improved patient experience and compliance. The company serves a diverse clientele, including patients, employers, health insurers, government agencies, and public health organizations, focusing on creating personalized and satisfying healthcare experiences.
Allevi develops tools for designing and engineering 3D tissues, specializing in desktop 3D bioprinters that create functional living tissues. The company's offerings include bioinks composed of collagen and hyaluronic acid, alongside a cloud-based platform called Bioprint Online, which allows users to design structures, define materials, and monitor the printing process. Allevi's products are utilized by researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as by industrial and pharmaceutical companies for drug testing and development. The company's bioinks are available for purchase online. Founded in 2014 and based in Philadelphia, Pennsylvania, Allevi was previously known as BioBots, Inc.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.
Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis.
Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.
Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria.
Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections.
Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis.
Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Microbiota
Seed Round in 2013
Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
Ossianix Inc. is a biotherapeutics company that specializes in developing single domain antibodies derived from the VNAR structure of sharks. Founded in 2012 and headquartered in Philadelphia, Pennsylvania, with research facilities in Stevenage, United Kingdom, Ossianix utilizes its VNAR platform to create high-affinity products that address various therapeutic targets. This innovative approach allows for the rapid development of bispecific and trispecific antibodies, which can be tailored for specific clinical applications, including targeting the blood-brain barrier and gastrointestinal tract. The company has also established a strategic research collaboration with Lundbeck A/S to advance its drug discovery programs across different therapeutic areas.
Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis.
Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Life Mist Technologies, Inc., doing business as LMT, develops and commercializes an atomization technology that uses low pressure gas and liquid to produce a high volume of micron sized droplets. The company focuses on using its technology in various industrial applications, such as aircraft fire suppression, chemical processing, emission control, fire suppression, decontamination, turbine inlet cooling, artificial snow, and cooling. Life Mist Technologies was incorporated in 2004 and is based in Paoli, Pennsylvania.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis.
Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.
Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.
Anakim
Seed Round in 2012
Anakim Biologics is developing efficiencies and improvements in biologics manufacturing;
TREVENTIS™ Corporation is an early stage biotechnology company focused on diseases associated with protein misfolding such as Alzheimer’s, Parkinson’s and Huntington’s. Currently, the Company has two major areas of discovery and development including: (1) the development of drugs that halt Alzheimer’s disease (and other dementias) progression with the promise of stabilizing or improving cognition and (2) the development of companion diagnostics for detection of AD to allow for early drug intervention to minimize neuronal loss.
Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, that specializes in developing protein-based nanotechnology for various applications, including targeted therapeutics, biosensors, and functional biomaterials. Founded in 2003, the company offers a platform called TriPol, which consists of modular components designed from proteins. This platform enables the construction of diverse nanostructures by leveraging the unique properties of proteins, such as their capability for self-assembly with atomic precision and their structural diversity. Imiplex utilizes recombinant DNA technology for engineering these proteins, ensuring scalable production and versatility in its applications.
COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.
CarePartners Plus LLC is a healthcare data and information company based in Horsham, Pennsylvania, established in 2009. The company specializes in patient management solutions, offering Wellby, a cloud-based patient engagement system designed to enhance health outcomes by facilitating better patient-provider interactions. CarePartners Plus provides a range of services including patient engagement, caregiver management, care coordination, and cost containment, aimed at hospitals, physician groups, and various stakeholders in the healthcare system. Its technology captures and analyzes patient-generated data in real time, aligning with business models that prioritize improved patient experience and compliance. The company serves a diverse clientele, including patients, employers, health insurers, government agencies, and public health organizations, focusing on creating personalized and satisfying healthcare experiences.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.
RMH Sciences
Seed Round in 2012
RMH Sciences aims to commercialize newly discovered antibiotics by Dr. Harvey Rubin, University of Pennsylvania Professor of Medicine. One of RMH’s most promising ventures focuses on creating antibiotics to combat hospital acquired bacterial pathogens, a largely unmet need in the current marketplace.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.
Formae, Inc. develops products in arthroscopic joint resurfacing and replacement. It offers ArthroPad, a biocompatible implant offering an arthroscopic minimally invasive surgical option to replace damaged cartilage in arthritic joints. The company serves applications, such as arthritis and joint destructions. Formae, Inc. was founded in 2006 and is based in Paoli, Pennsylvania.
Phoenix S&T, Inc. designs, develops, and supplies nanospray and microspray systems for life research and drug discovery solutions. The company’s Nimbus and pneu-Nimbus NanoLC systems provide ionization for LC/MS experiments; clinical diagnostics; and homeland security. It offers column haters, column coolers, and emitters and columns. The company’s products are used in various applications, including proteomics, biomarkers, and direct infusion. It serves customers in Europe and China. The company was founded in 2001 and is based in Chadds Ford, Pennsylvania.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.